Erasca, Inc. recently reported first-quarter 2026 results showing a net loss of US$183.44 million, alongside expanded clinical progress for its oncology pipeline. Despite the larger loss, the company highlighted robust early efficacy and generally well-tolerated safety for ERAS-0015 and continued advancement of pan-KRAS candidate ERAS-4001, drawing positive commentary from JPMorgan. With ERAS-0015’s early efficacy profile in focus, we’ll now examine what these developments mean for Erasca’s...